Erratum: Incretin Mimetics Vie for Slice of Type 2 Diabetes Market

Nature Biotechnology - United Kingdom
doi 10.1038/nbt0407-478b
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes

European Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2007English

Which Incretin-Based Therapy for Type 2 Diabetes?

The Lancet
Medicine
2014English

Comparison of Efficacy Between Incretin-Based Therapies for Type 2 Diabetes Mellitus

BMC Medicine
Medicine
2012English

Incorporating Incretin-Based Therapies Into Clinical Practice for Patients With Type 2 Diabetes

Advances in Therapy
MedicinePharmacology
2014English

Role of Incretin‐based Therapy in Hospitalized Patients With Type 2 Diabetes

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2019English

Erratum To: Pharmacokinetics in Patients With Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

Clinical Pharmacokinetics
Pharmacology
2014English

Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes

Vascular Health and Risk Management
PharmacologyCardiologyEndocrinologyPublic HealthHematologyEnvironmentalCardiovascular MedicineMedicineOccupational HealthMetabolismDiabetes
2006English

TCF7L2 Variant Rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2009English

Association of Type 2 Diabetes Candidate Polymorphisms in KCNQ1 With Incretin and Insulin Secretion

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy